{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T02:16:20Z","timestamp":1716948980672},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1986,1,1]],"date-time":"1986-01-01T00:00:00Z","timestamp":504921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1986,1]]},"DOI":"10.1007\/bf00255278","type":"journal-article","created":{"date-parts":[[2004,9,19]],"date-time":"2004-09-19T05:43:18Z","timestamp":1095572598000},"page":"1-8","source":"Crossref","is-referenced-by-count":21,"title":["CB 1954 revisited"],"prefix":"10.1007","volume":"16","author":[{"given":"Paul","family":"Workman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A. S.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00255278_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2307\/3574491","volume":"67","author":"GE Adams","year":"1976","unstructured":"Adams GE, Flockhart IR, Smithen CE, Stratford IJ, Wardman P, Watts ME (1976) Electron-affinic sensitization: VII. A correlation between structure, one-electron reduction potentials and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res 67: 9","journal-title":"Radiat Res"},{"key":"BF00255278_CR2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/bjc.1984.91","volume":"49","author":"GE Adams","year":"1984","unstructured":"Adams GE, Ahmed I, Sheldon PW, Stratford JJ (1984) Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer 49: 571\u2013577","journal-title":"Br J Cancer"},{"key":"BF00255278_CR3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0006-2952(79)90142-4","volume":"28","author":"MR Boyd","year":"1979","unstructured":"Boyd MR, Stiko AW, Sasame HA (1979) Metabolic activation of nitrofuration\u2014possible implications for carcinogenesis. Biochem Pharmacol 28: 601\u2013606","journal-title":"Biochem Pharmacol"},{"key":"BF00255278_CR4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2307\/3575246","volume":"82","author":"JM Brown","year":"1980","unstructured":"Brown JM, Workman P (1980) Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res 82: 171","journal-title":"Radiat Res"},{"key":"BF00255278_CR5","first-page":"956","volume":"1","author":"GAM Butchart","year":"1978","unstructured":"Butchart GAM, Stevens MFG, Gunn BC (1978) Medicinal nitrocompounds: II. Search for ortho-interactions in tumour-inhibitory 2,4-dintrophenylaziridines. J Chem Soc Perkin Trans 1: 956\u2013963","journal-title":"J Chem Soc Perkin Trans"},{"key":"BF00255278_CR6","first-page":"885","volume-title":"Radiation research: Proceedings of the 6th International Congress of Radiation Research, Tokyo","author":"JD Chapman","year":"1979","unstructured":"Chapman JD, Raleigh JA, Pedersen JE, Ngan J, Shum FY, Meeker BE, Urtasun RC (1979) Potentially three distinct roles for hypoxic cell sensitizers in the clinic. In: Okada S, Imumura M, Terashima T, Yamaguchi H (eds) Radiation research: Proceedings of the 6th International Congress of Radiation Research, Tokyo. Japanese Association for Radiation Research, Tokyo, pp 885\u2013892"},{"key":"BF00255278_CR7","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/0006-2952(69)90267-6","volume":"18","author":"LM Cobb","year":"1969","unstructured":"Cobb LM, Connors TA, Elson LA, Khan AH, Mitchley BCV, Ross WCJ, Whisson ME (1969) 2,4-Dinitro-5-ethylene iminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem Pharmacol 18: 1519\u20131527","journal-title":"Biochem Pharmacol"},{"key":"BF00255278_CR8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ijc.2910070110","volume":"7","author":"TA Connors","year":"1971","unstructured":"Connors TA, Melzack DH (1971) Studies on the mechanism of action of 5-aziridinyl-2,4-dinitrobenzamide (CB 1954), a selective inhibitor of the Walker tumour. Int J Cancer 7: 86\u201392","journal-title":"Int J Cancer"},{"key":"BF00255278_CR9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/ijc.2910090115","volume":"9","author":"TA Connors","year":"1972","unstructured":"Connors TA, Mandel HG, Melzack DH (1972) Studies on the reversal of the selective anti-tumour effect of the aziridinyl derivative CB 1954 by 4-amino-5-imidazole carboxamide. Int J Cancer 9: 126\u2013132","journal-title":"Int J Cancer"},{"key":"BF00255278_CR10","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/0006-2952(75)90380-9","volume":"24","author":"JA Hickman","year":"1975","unstructured":"Hickman JA, Melzack DH (1975) Protection against the effects of the antitumour agent CB 1954 by certain imidazoles and related compounds. Biochem Pharmacol 24: 1947\u20131952","journal-title":"Biochem Pharmacol"},{"key":"BF00255278_CR11","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/0006-2952(76)90451-2","volume":"25","author":"M Jarman","year":"1976","unstructured":"Jarman M, Melzack DH, Ross WCJ (1976) The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954). Biochem Pharmacol 25: 2475\u20132478","journal-title":"Biochem Pharmacol"},{"key":"BF00255278_CR12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0009-2797(69)90017-9","volume":"1","author":"AH Khan","year":"1969\/70","unstructured":"Khan AH, Ross WCJ (1969\/70) Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure- activity relationships. Chem Biol Interact 1: 27\u201347","journal-title":"Chem Biol Interact"},{"key":"BF00255278_CR13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0009-2797(71)90029-9","volume":"4","author":"AH Khan","year":"1971\/72","unstructured":"Khan AH, Ross WCJ (1971\/72) Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships: II. Chem Biol Interact 4: 11\u201322","journal-title":"Chem Biol Interact"},{"key":"BF00255278_CR14","first-page":"2704","volume":"35","author":"L Kopper","year":"1975","unstructured":"Kopper L, Steel GG (1975) The therapeutic response of three human lines maintained in immune-suppressed mice. Cancer Res 35: 2704","journal-title":"Cancer Res"},{"key":"BF00255278_CR15","first-page":"275","volume":"34","author":"HG Mandel","year":"1974","unstructured":"Mandel HG, Connors TA, Melzack DH, Merai K (1974) Studies on the mechanism of action of 5-aziridinyl-2,4-dinitrobenzamide in tumour cells. Cancer Res 34: 275\u2013280","journal-title":"Cancer Res"},{"key":"BF00255278_CR16","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1016\/0006-2952(69)90202-0","volume":"18","author":"WCJ Ross","year":"1969","unstructured":"Ross WCJ (1969) A spectrophotometric method for the estimation of the carcinostatic agent 5-aziridino-2,4-dinitrobenzamide (CB 1954) in biological fluids. Biochem Pharmacol 18: 2683\u20132688","journal-title":"Biochem Pharmacol"},{"key":"BF00255278_CR17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2307\/3575639","volume":"88","author":"IJ Stratford","year":"1981","unstructured":"Stratford IJ, Williamson C, Hoe S, Adams GE (1981) Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide). Radiat Res 88: 502\u2013509","journal-title":"Radiat Res"},{"key":"BF00255278_CR18","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/0006-2952(80)90021-0","volume":"29","author":"MJ Tisdale","year":"1980","unstructured":"Tisdale MJ, Habberfield AD, (1980) Selective inhibition of ribonucleotide reductase by the monofunctional alkylating agent 5(1-aziridinyl)-2, 4-dinitrobenzamide (CB 1954). Biochem Pharmacol 29: 2845\u20132853","journal-title":"Biochem Pharmacol"},{"key":"BF00255278_CR19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/bjc.1975.251","volume":"32","author":"PR Twentyman","year":"1975","unstructured":"Twentyman PR, Bleehen NM (1975) Studies of potentially lethal damage in EMT6 mouse tumour cells treated with bleomycin either in vitro or in vivo. Br J Cancer 32: 491","journal-title":"Br J Cancer"},{"key":"BF00255278_CR20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0360-3016(79)90649-7","volume":"5","author":"PR Twentyman","year":"1979","unstructured":"Twentyman PR, Kallman RF, Brown JM (1979) The effect of time between x-irradiation and chemotherapy ont he growth of three solid mouse tumours: I. Adriamycin. Int J Radiat Oncol Biol Phys 5: 1255","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF00255278_CR21","first-page":"595","volume":"64","author":"PR Twentyman","year":"1980","unstructured":"Twentyman PR, Brown JM, Gray JW, Franko AJ, Scoles MA, Kallman RR (1980) A new mouse model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst 64: 595\u2013604","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl IV","key":"BF00255278_CR22","first-page":"128","volume":"41","author":"HM Warenius","year":"1980","unstructured":"Warenius HM, Freedman LS, Bleehen NM (1980) The response of a human tumour xenograft to chemotherapy: Intrinsic variation between tumours and its significance in planning experiments. Br J Cancer 41 [Suppl IV]: 128","journal-title":"Br J Cancer"},{"key":"BF00255278_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF00578559","volume":"5","author":"P Workman","year":"1980","unstructured":"Workman P (1980) Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. Cancer Pharmacol 5: 27","journal-title":"Cancer Pharmacol"},{"key":"BF00255278_CR24","first-page":"291","volume-title":"Pharmacokinetics of anticancer agents in humans","author":"P Workman","year":"1983","unstructured":"Workman P (1983) Pharmacokinetics of radiosensitizing agents. In: Ames MM, Powis G, Kovach JS (eds) Pharmacokinetics of anticancer agents in humans. Elsevier, Amsterdam, pp 291\u2013362"},{"key":"BF00255278_CR25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00253009","volume":"6","author":"P Workman","year":"1981","unstructured":"Workman P, Brown JM (1981) Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol 6: 39","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00255278_CR26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/bjc.1980.43","volume":"41","author":"P Workman","year":"1980","unstructured":"Workman P, White RAS (1980) Pharmacokinetics and tumour-penetration properties of the hypoxic cell radiosensitzer desmethylmisonidazole (Ro 05-9963) in dogs. Br J Cancer 41: 268","journal-title":"Br J Cancer"},{"key":"BF00255278_CR27","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/0006-2952(82)90077-6","volume":"31","author":"P Workman","year":"1982","unstructured":"Workman P, White RAS (1982) The effects of the xanthine oxidase inhibitor allopurinol on the renal clearance of nitroimidazoles. Biochem Pharmacol 31: 3041\u20133046","journal-title":"Biochem Pharmacol"},{"key":"BF00255278_CR28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0378-4347(00)81386-9","volume":"145","author":"P Workman","year":"1978","unstructured":"Workman P, Little CJ, Marten TR, Dale AD, Ruane RJ, Flockhart IR, Bleehen NM (1978) Estimation of the hypoxic cell-sensitizer misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr 145: 507\u2013512","journal-title":"J Chromatogr"},{"key":"BF00255278_CR29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/bjc.1984.176","volume":"50","author":"P Workman","year":"1984","unstructured":"Workman P, White RAS, Walton MI, Owen LN, Twentyman PR (1984) Preclinical pharmacokinetics of benznidazole. Br J Cancer 50: 291\u2013303","journal-title":"Br J Cancer"},{"key":"BF00255278_CR30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00255279","volume":"16","author":"P Workman","year":"1986","unstructured":"Workman P, Morgan JE, Talbot K, Wright KA, Donaldson J, Twentyman PR (1986) CB 1954 revisited: II. Toxicity and antitumour activity. Cancer Chemother Pharmacol 16: 9\u201314","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00255278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00255278\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00255278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T15:57:22Z","timestamp":1554307042000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00255278"}},"subtitle":["I. Disposition kinetics and metabolism"],"short-title":[],"issued":{"date-parts":[[1986,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1986,1]]}},"alternative-id":["BF00255278"],"URL":"https:\/\/doi.org\/10.1007\/bf00255278","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986,1]]}}}